The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Potapov A.L.

A.F. Tsyb Medical Radiological Research Center, a Branch National Medical Research Center for Radiology under the Ministry of Health of the Russian Federation, Obninsk, Russia

Boyarkina A.V.

A.F. Tsyb Medical Radiology Research Centre, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia

Role of μ1-opioid receptor and its genetic polymorphism in patients with cancers

Authors:

Potapov A.L., Boyarkina A.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2016;5(3): 76‑79

DOI: 10.17116/onkolog20165376-79

Read: 1215 times

Download PDF (RU)
Contact the author
Table of contents

ROLE OF Μ1-OPIOID RECEPTOR AND ITS GENETIC POLYMORPHISM IN PATIENTS WITH CANCERS
ROLE OF Μ1-OPIOID RECEPTOR AND ITS GENETIC POLYMORPHISM IN PATIENTS WITH CANCERS

To cite this article:

Potapov AL, Boyarkina AV. Role of μ1-opioid receptor and its genetic polymorphism in patients with cancers. P.A. Herzen Journal of Oncology. 2016;5(3):76‑79. (In Russ.)
https://doi.org/10.17116/onkolog20165376-79

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The literature review considers the role of μ1-opioid receptor (OPRM1) and its genetic polymorphism in patients with cancers. The present knowledge suggests that OPRM1 is of value in treating pain and cancer progression. The 118A>G single nucleotide polymorphism in the OPRM1 gene affects postoperative opioid analgesia and may be related to some forms of malignancy.

Keywords:

μ1-opioid receptor
genetic polymorphism
malignancies

Authors:

Potapov A.L.

A.F. Tsyb Medical Radiological Research Center, a Branch National Medical Research Center for Radiology under the Ministry of Health of the Russian Federation, Obninsk, Russia

Boyarkina A.V.

A.F. Tsyb Medical Radiology Research Centre, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia

Close metadata

References:

  1. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth. 2012;109(Suppl.1):i17-i28.  doi:10.1093/bja/aes421.
  2. Gach K, Wyrebska A, Fichna J, Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(3):221-230.  doi:10.1007/s00210-011-0672-4.
  3. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014;113(Suppl.1):i103-i108. doi:10.1093/bja/aeu165.
  4. Zylla D, Gourley BL, Vang D. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013;119(23):4103-4110. doi:10.1002/cncr.2834.
  5. Kraus J. Regulation of mu-opioid receptors by cytokines. Front Biosci (Schol Ed). 2009;1:164-170.  doi:10.2741/e16.
  6. Kaprin A, Abuzarova G, Khoronenko V, Alekseeva G, Kostin A, Starinskii V, Alekseev B. Pharmacotherapy of chronic pain in adult patients in palliative care in-patient and out-patient conditions. Guidelines Farmakoterapiya khronicheskogo bolevogo sindroma u vzroslykh patsientov pri okazanii palliativnoi pomoshchi v statsionarnykh i ambulatorno-poliklinicheskikh usloviyakh]. M.: FGBU «MNIOI im. P.A. Gertsena»; 2015. (In Russ.)
  7. Zylla D, Kuskowski M, Gupta K, Gupta P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113(Suppl.1):i109-i116. doi:10.1093/bja/aeu351.
  8. Pasternak G. Molecular insights into μ- opioid pharmacology: from the clinic to the bench. Clin J Pain. 2010;26(Suppl.10):S3-S9.  doi:10.1097/ajp.0b013e3181c49d2e.
  9. Arbak D, Abuzarova G, Alekseeva G. Opioid analgesics in XXI century clinical medicine. Rossiiskii zhurnal boli. 2014;2:39-50. (In Russ.)
  10. De Gregori M, Diatchenko L, Belfer I, Allegri M. OPRM1 receptor as new biomarker to help the prediction of post mastectomy pain and recurrence in breast cancer. Minerva Anestesiol. 2015;81(8):894-900. PMID: 25300626.
  11. Al-Hashimi M, Scott S, Thompson J, Lambert D. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013;111(1):80-88.  doi:10.1093/bja/aet153.
  12. Abakushina E, Kuz'mina E, Kovalenko E. The main characteristics of human natural killer cells. Immunologiya. 2012; 4:220-224. (In Russ.)
  13. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S et al. The novel role of the mu-opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011;112(3):558-567.  doi:10.1213/ANE.0b013e31820568af.
  14. Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RH. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res. 2013;6:331-353.  doi:10.2147/JPR.S42040.
  15. Potapov A, Boyarkina A. M1-opioid receptor and catechol-o-metiltransferase genes polymorphism effects on perioperative psychological condition of the patients and the effectiveness of postoperative analgesia with opioids. Anesteziologiya i reanimatologiya. 2015; 3:48-51. PMID: 26415297. (In Russ.)
  16. Zhenilo V, Makharin O. The Influence of gene polymorphism OPRM1 118A/G on the perception of pain and pharmacodynamics of narcotic analgesics. Obshchaya reanimatologiya. 2014;10(1):58-63. (In Russ.) doi:10.15360/1813-9779-2014-1-58-67.
  17. Trescot MA, Faynboym S. A review of the role of genetic testing in pain medicine. Pain Physician. 2014;17(5):425-445. PMID: 25247900.
  18. Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain. 2009;146(3):270-275.  doi:10.1016/j.pain.2009.07.013. 
  19. Hwang I, Park J, Myung S, Ahn H, Fukuda K, Liao Q. OPRM1 A118G gene variant and postoperative opioid requirement. Anesthesiology. 2014;121(4):825-834.  doi:10.1097/aln.0000000000000405.
  20. Ren ZY, Xu XQ, Bao YP, He J, Shi L, Deng JH et al. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Physician. 2015;18(2):131-152. PMID: 25794200.
  21. Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC et al. The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232-1239. doi:10.1111/j.1399-6576.2004.00517.x.
  22. Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5(5):324-336.  doi:10.1038/sj.tpj.6500327.
  23. Song Z, Du B, Wang K, Shi X. Effects of OPRM1 A118G polymorphism on epidural analgesia with fentanyl during labor: a meta-analysis. Genet Test Mol Biomarkers. 2013;17(10):743-749.  doi:10.1089/gtmb.2013.0282.
  24. Bortsov A, Millikan R, Belfer I, Boortz-Marx R, Arora H, McLean S. μ-opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology. 2012;116(4):896-902.  doi:10.1097/aln.0b013e31824b96a1.
  25. Cieślińska A, Sienkiewicz-Szłapka E, Kostyra E, Fiedorowicz E, Snarska J, Wroński K et al. μ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer. Tumor Biol. 2015;36(6):4655-4660. doi:10.1007/s13277-015-3113-z.
  26. Wang S, Li Y, Liu X, Zhao C, Yang K. Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol. 2013;18(4):666-669.  doi:10.1007/s10147-012-0441-5.
  27. Cakmakkaya OS, Kolodzie K, Apfel CC, Pace NL. Anaesthetic techniques for risk of malignant tumour recurrence. Cochrane Database Syst Rev. 2014;(11):CD008877. doi:10.1002/14651858.CD008877.pub2.
  28. Singleton P, Moss J, Karp D, Atkins J, Janku F. The mu-opioid receptor: a new target for cancer therapy? Cancer. 2015;121(16):2681-2688. doi:10.1002/cncr.29460.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.